Detalles de la búsqueda
1.
Meta-analysis of pharmacogenetic clinical decision support systems for the treatment of major depressive disorder.
Pharmacogenomics J
; 23(2-3): 45-49, 2023 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-36273107
2.
CYP3A4*22 and CYP3A5*3 impact efficacy and safety of diazepam in patients with alcohol withdrawal syndrome.
Nord J Psychiatry
; 77(1): 73-76, 2023 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-35471917
3.
Investigating the Use of Pharmacogenetic and Pharmacometabolomic Markers to Predict Haloperidol Efficacy and Safety Rates.
Hosp Pharm
; 58(4): 363-367, 2023 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-37360210
4.
The Association between the Alcohol Biomarker Phosphatidylethanol (PEth) and Self-Reported Alcohol Consumption among Russian and Norwegian Medical Patients.
Alcohol Alcohol
; 56(6): 726-736, 2021 Oct 29.
Artículo
en Inglés
| MEDLINE | ID: mdl-33677484
5.
Effects of CYP2C19*17 Genetic Polymorphisms on the Steady-State Concentration of Diazepam in Patients With Alcohol Withdrawal Syndrome.
Hosp Pharm
; 56(5): 592-596, 2021 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-34720165
6.
Using a personalized clinical decision support system for bromdihydrochlorphenylbenzodiazepine dosing in patients with anxiety disorders based on the pharmacogenomic markers.
Hum Psychopharmacol
; 33(6): e2677, 2018 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-30357930
7.
Translating and adapting the Alcohol Use Disorders Identification Test (AUDIT) for use in the Russian Federation: A multicentre pilot study to inform validation procedures.
Nordisk Alkohol Nark
; 40(5): 536-553, 2023 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-37969901
8.
Effects of CYP2D6*4 polymorphism on the steady-state concentration of paroxetine in patients diagnosed with depressive episode and comorbid alcohol use disorder.
J Psychopharmacol
; 36(10): 1146-1150, 2022 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-35861192
9.
Effects of CYP2C19*17 genetic polymorphisms on plasma and saliva concentrations of diazepam in patients with alcohol withdrawal syndrome.
Psychiatr Genet
; 32(2): 67-73, 2022 04 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-35001019
10.
Using the CYP3A Activity Evaluation to Predict the Efficacy and Safety of Diazepam in Patients With Alcohol Withdrawal Syndrome.
J Pharm Pract
; 35(4): 518-523, 2022 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-33622083
11.
Genetic testing is superior over endogenous pharmacometabolomic markers to predict safety of haloperidol in patients with alcohol-induced psychotic disorder.
Curr Drug Metab
; 2022 Dec 28.
Artículo
en Inglés
| MEDLINE | ID: mdl-36579390
12.
Impact of CYP2D6 Polymorphism on Equilibrium Concentration of Fluoxetine in Patients Diagnosed With Major Depressive Disorder and Comorbid Alcohol Use Disorders.
J Psychiatr Pract
; 27(5): 372-379, 2021 09 16.
Artículo
en Inglés
| MEDLINE | ID: mdl-34529603
13.
Using a pharmacogenetic clinical decision support system to improve psychopharmacotherapy dosing in patients with affective disorders.
Drug Metab Pers Ther
; 35(4)2020 09 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-32870807
14.
Predictors of tobacco smoking among acutely ill patients in a Moscow hospital: A cross-sectional study.
Tob Prev Cessat
; 6: 18, 2020.
Artículo
en Inglés
| MEDLINE | ID: mdl-32548355
15.
How do CYP2C19*2 and CYP2C19*17 genetic polymorphisms affect the efficacy and safety of diazepam in patients with alcohol withdrawal syndrome?
Drug Metab Pers Ther
; 35(1)2020 03 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-32134726
16.
CYP3A subfamily activity affects the equilibrium concentration of Phenazepam® in patients with anxiety disorders and comorbid alcohol use disorder.
Pharmacogenomics
; 21(7): 449-457, 2020 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-32336193
17.
Prevalence of psychoactive substance use among acutely hospitalised patients in Oslo and Moscow: a cross-sectional, observational study.
BMJ Open
; 10(9): e032572, 2020 09 17.
Artículo
en Inglés
| MEDLINE | ID: mdl-32948540
18.
Effects of CYP2D6 genetic polymorphisms on the efficacy and safety of fluvoxamine in patients with depressive disorder and comorbid alcohol use disorder.
Pharmgenomics Pers Med
; 11: 113-119, 2018.
Artículo
en Inglés
| MEDLINE | ID: mdl-29988737
19.
The influence of CYP3A5 polymorphisms on haloperidol treatment in patients with alcohol addiction.
Pharmgenomics Pers Med
; 11: 1-5, 2018.
Artículo
en Inglés
| MEDLINE | ID: mdl-29343979
20.
Effects of CYP2C19*17 polymorphisms on the efficacy and safety of bromodigyrochlorophenylbenzodiazepine in patients with anxiety disorder and comorbid alcohol use disorder.
Drug Metab Pers Ther
; 33(4): 187-194, 2018 12 19.
Artículo
en Inglés
| MEDLINE | ID: mdl-30325732